TORONTO, March 21, 2023 /CNW/ - LifeSpeak Inc. ("LifeSpeak" or the "Company") (TSX: LSPK), the leading, whole-person- wellbeing solution for employers, health plans, and insurance companies, announced today that it will release its fourth quarter and full year 2022 financial results before market open on Friday, March 31, 2023.
The Company will subsequently hold a conference call to provide a business update on Friday, March 31, 2023, at 8:00 a.m. ET hosted by:
A question-and-answer session will follow the business update.
CONFERENCE CALL DETAILS | |
DATE: | Friday, March 31, 2023 |
TIME: | 8:00 a.m. ET |
DIAL-IN NUMBERS: | 1.833.950.0062 or 1.833.470.1428 |
REFERENCE NUMBER: | 194062 |
This live call is also being webcast and can be accessed by going to:
https://events.q4inc.com/attendee/710357881
An archived telephone replay of the call will be available for two weeks by dialing 1.226.828.7578 or 1.866.813.9403 and entering access code 730209.
LifeSpeak is the leading whole-person-wellbeing platform for employers and other organizations that brings together digital education with human support. Our suite of wellbeing products allows organizations to provide best-in-class content and expertise that scales, meeting each individual wherever they are on their personal wellbeing journeys. As the parent company to LIFT Digital, ALAViDA Health, Torchlight, and Wellbeats, LifeSpeak provides in-depth expertise across mental health, wellness, physical fitness, substance use, and caregiving. With more than 30 years of collective experience working directly with Fortune 500 companies, government agencies, insurance providers, and others across the globe, we understand the complexities of addressing wellbeing within organizations, which is why our digital and data-driven approach provides insights that uncover gaps in wellbeing at the organizational level, ultimately enhancing performance outcomes. To learn more, follow LifeSpeak on LinkedIn (http://www.linkedin.com/company/lifespeak-inc), or visit www.LifeSpeak.com.
Last Trade: | C$0.20 |
Daily Change: | 0.03 14.71 |
Daily Volume: | 1,500 |
Market Cap: | C$11.530M |
March 31, 2025 November 07, 2024 May 08, 2024 March 21, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load